Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: A project of the Kyushu University Liver Diseases Study Group

Norihiro Furusyo, Masaki Katoh, Yuichi Tababe, Eiji Kajiwara, Toshihiro Maruyama, Junya Shimono, Hironori Sakai, Makoto Nakamuta, Hideyuki Nomura, Akihide Masumoto, Shinji Shimoda, Kazuhiro Takahashi, Koichi Azuma, Jun Hayashi, H. Nakashima, M. Murata, K. Toyoda, H. Takeoka, T. Kuga, A. MitsutakeR. Sugimoto, H. Amagase, S. Tominaga, K. Yanagita, K. Ogiwara, M. Tokumatsu, S. Tabata, M. Yokota, H. Tanaka, S. Nagase, S. Tsuruta, S. Tada, M. Nagano, M. Honda, T. Umeno, T. Sugimura, S. Ueno, K. Miki, H. Okubo, H. Fujimoto, N. Higuchi, S. Shigematsu, N. Higashi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Aim: To determine the efficacy of an interferon alpha and ribavirin combination treatment for Japanese patients infected with hepatitis C virus (HCV) of genotype 2, a multi-center study was retrospectively analyzed. Methods: In total, 173 patients with HCV genotype 2 started to receive interferon-alpha subcutaneously thrice a week and 600-800 mg of ribavirin daily for 24 wk. Results: The overall sustained virological response (SVR), defined as undetectable HCV RNA in serum, 24 wk after the end of treatment, was remarkably high by 84.4%, (146/173) by an intention-to-treat analysis. A significant difference in SVR was found between patients with and without the discontinuation of ribavirin (46.9% vs 92.9%), but no difference was found between those with and without a dose reduction of ribavirin. A significant difference in SVR was also found between patients with less than 16 wk and patients with 16 or more weeks of ribavirin treatment (34.8% vs 92.0%). Conclusion: The 24-wk interferon and ribavirin treatment is highly effective for Japanese patients with HCV genotype 2. The significant predictor of SVR is continuation of the ribavirin treatment for up to 16 weeks.

Original languageEnglish
Pages (from-to)784-790
Number of pages7
JournalWorld Journal of Gastroenterology
Volume12
Issue number5
DOIs
Publication statusPublished - Feb 7 2006

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Fingerprint Dive into the research topics of 'Interferon alpha plus ribavirin combination treatment of Japanese chronic hepatitis C patients with HCV genotype 2: A project of the Kyushu University Liver Diseases Study Group'. Together they form a unique fingerprint.

Cite this